These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 21270199)

  • 1. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.
    Nin JW; Jorsal A; Ferreira I; Schalkwijk CG; Prins MH; Parving HH; Tarnow L; Rossing P; Stehouwer CD
    Diabetes Care; 2011 Feb; 34(2):442-7. PubMed ID: 21270199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.
    Nin JW; Jorsal A; Ferreira I; Schalkwijk CG; Prins MH; Parving HH; Tarnow L; Rossing P; Stehouwer CD
    Diabetes; 2010 Aug; 59(8):2027-32. PubMed ID: 20522598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12 year follow-up study.
    Nin JW; Ferreira I; Schalkwijk CG; Jorsal A; Prins MH; Parving HH; Tarnow L; Rossing P; Stehouwer CD
    Diabetologia; 2012 Sep; 55(9):2489-93. PubMed ID: 22752054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease in Individuals With Type 1 Diabetes: A 12-Year Follow-up Study.
    Hanssen NMJ; Scheijen JLJM; Jorsal A; Parving HH; Tarnow L; Rossing P; Stehouwer CDA; Schalkwijk CG
    Diabetes; 2017 Aug; 66(8):2278-2283. PubMed ID: 28588100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study.
    Peeters SA; Engelen L; Buijs J; Jorsal A; Parving HH; Tarnow L; Rossing P; Schalkwijk CG; Stehouwer CDA
    Cardiovasc Diabetol; 2017 Apr; 16(1):55. PubMed ID: 28446168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between advanced glycation endproducts and matrix metalloproteinases and its inhibitor in individuals with type 1 diabetes.
    Peeters SA; Engelen L; Buijs J; Theilade S; Rossing P; Schalkwijk CG; Stehouwer CDA
    J Diabetes Complications; 2018 Mar; 32(3):325-329. PubMed ID: 29395841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arterial Stiffness Predicts Mortality in Individuals With Type 1 Diabetes.
    Tynjälä A; Forsblom C; Harjutsalo V; Groop PH; Gordin D;
    Diabetes Care; 2020 Sep; 43(9):2266-2271. PubMed ID: 32647049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.
    Lajer M; Tarnow L; Jorsal A; Teerlink T; Parving HH; Rossing P
    Diabetes Care; 2008 Apr; 31(4):747-52. PubMed ID: 18162497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes.
    Koska J; Saremi A; Howell S; Bahn G; De Courten B; Ginsberg H; Beisswenger PJ; Reaven PD;
    Diabetes Care; 2018 Mar; 41(3):570-576. PubMed ID: 29208654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Advanced Glycation Endproducts and Long-Term Risk of Cardiovascular Mortality in Kidney Transplant Recipients.
    Sotomayor CG; Gomes-Neto AW; van Londen M; Gans ROB; Nolte IM; Berger SP; Navis GJ; Rodrigo R; Leuvenink HGD; Schalkwijk CG; Bakker SJL
    Clin J Am Soc Nephrol; 2019 Oct; 14(10):1512-1520. PubMed ID: 31530552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dietary saturated fat and fibre and risk of cardiovascular disease and all-cause mortality among type 1 diabetic patients: the EURODIAB Prospective Complications Study.
    Schoenaker DA; Toeller M; Chaturvedi N; Fuller JH; Soedamah-Muthu SS;
    Diabetologia; 2012 Aug; 55(8):2132-41. PubMed ID: 22526612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of placental growth factor and soluble Fms-like tyrosine kinase 1 as predictors of all-cause and cardiovascular mortality in patients with Type 1 diabetes with and without diabetic nephropathy.
    Theilade S; Lajer M; Jorsal A; Tarnow L; Parving HH; Rossing P
    Diabet Med; 2012 Mar; 29(3):337-44. PubMed ID: 21988672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein glycation products associate with progression of kidney disease and incident cardiovascular events in individuals with type 1 diabetes.
    Adeshara K; Gordin D; Antikainen AA; Harjutsalo V; Sandholm N; Lehto MJ; Groop PH;
    Cardiovasc Diabetol; 2024 Jul; 23(1):235. PubMed ID: 38965604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study.
    Nin JW; Ferreira I; Schalkwijk CG; Prins MH; Chaturvedi N; Fuller JH; Stehouwer CD;
    Diabetologia; 2009 Apr; 52(4):705-14. PubMed ID: 19183936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skin autofluorescence, arterial stiffness and Framingham risk score as predictors of clinical outcome in chronic kidney disease patients: a cohort study.
    Mukai H; Svedberg O; Lindholm B; Dai L; Heimbürger O; Barany P; Anderstam B; Stenvinkel P; Qureshi AR
    Nephrol Dial Transplant; 2019 Mar; 34(3):442-448. PubMed ID: 29378035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy.
    Galsgaard J; Persson F; Hansen TW; Jorsal A; Tarnow L; Parving HH; Rossing P
    Kidney Int; 2017 Nov; 92(5):1242-1248. PubMed ID: 28712855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of serum and dietary advanced glycation endproducts in relation to cardiac function and structure: The Hoorn Study.
    Kremers SHM; Remmelzwaal S; Schalkwijk CG; Elders PJM; Stehouwer CDA; van Ballegooijen AJ; Beulens JWJ
    Nutr Metab Cardiovasc Dis; 2021 Oct; 31(11):3167-3175. PubMed ID: 34518083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults.
    Semba RD; Bandinelli S; Sun K; Guralnik JM; Ferrucci L
    J Am Geriatr Soc; 2009 Oct; 57(10):1874-80. PubMed ID: 19682127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteopontin is a strong predictor of incipient diabetic nephropathy, cardiovascular disease, and all-cause mortality in patients with type 1 diabetes.
    Gordin D; Forsblom C; Panduru NM; Thomas MC; Bjerre M; Soro-Paavonen A; Tolonen N; Sandholm N; Flyvbjerg A; Harjutsalo V; Groop PH;
    Diabetes Care; 2014 Sep; 37(9):2593-600. PubMed ID: 24969575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Markers of inflammation and endothelial dysfunction are associated with incident cardiovascular disease, all-cause mortality, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria.
    von Scholten BJ; Reinhard H; Hansen TW; Schalkwijk CG; Stehouwer C; Parving HH; Jacobsen PK; Rossing P
    J Diabetes Complications; 2016 Mar; 30(2):248-55. PubMed ID: 26651261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.